

Marianne Vogsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5326786/publications.pdf>

Version: 2024-02-01

16
papers

188
citations

1163117

8
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

177
citing authors

#	ARTICLE	IF	CITATIONS
1	Learning from patient involvement in a clinical study analyzing PET/CT in women with advanced breast cancer. <i>Research Involvement and Engagement</i> , 2020, 6, 1.	2.9	41
2	A role of FDG-PET/CT for response evaluation in metastatic breast cancer?. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 520-530.	4.6	19
3	FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 145-153.	2.5	16
4	Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT. <i>British Journal of Cancer</i> , 2022, 126, 1271-1279.	6.4	15
5	Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study. <i>EJNMMI Research</i> , 2021, 11, 93.	2.5	14
6	FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond. <i>Cancers</i> , 2019, 11, 1190.	3.7	12
7	Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer. <i>Diagnostics</i> , 2020, 10, 1001.	2.6	10
8	FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST. <i>Diagnostics</i> , 2021, 11, 723.	2.6	10
9	Perspective of Patients with Metastatic Breast Cancer on Electronic Access to Scan Results: Mixed-Methods Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e15723.	4.3	10
10	FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. <i>Diagnostics</i> , 2019, 9, 106.	2.6	9
11	Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid Tissue. <i>European Thyroid Journal</i> , 2017, 6, 276-280.	2.4	8
12	Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 4080.	3.7	8
13	Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 433-446.	5.9	8
14	Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008–2012. <i>Acta Oncologica</i> , 2020, 59, 741-747.	1.8	4
15	Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures. <i>Diagnostics</i> , 2020, 10, 398.	2.6	4
16	Abstract P5-07-07: Mapping clonal evolution and tumor heterogeneity by whole exome sequencing of tissue and plasma circulating tumor DNA in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P5-07-07-P5-07-07.	0.9	0